利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.039 秒)

    Genetic alterations related to familial alzheimer's disease
    3.
    发明授权
    Genetic alterations related to familial alzheimer's disease 失效
    遗传改变与家族性阿尔茨海默病有关

    公开(公告)号：US06248555B1

    公开(公告)日：2001-06-19

    申请号：US08706344

    申请日：1996-08-30

    申请人： Rudolph Tanzi ,  Wilma Wasco

    发明人： Rudolph Tanzi ,  Wilma Wasco

    IPC分类号： C12N1512

    CPC分类号： C07K14/4711 ,  A01K2217/05

    摘要： Isolated nucleic acid molecules are provided encoding human PS1 gene products. Mutant PS1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of the activity of the PS1 polypeptide and mutants thereof. Also provided are diagnostic methods for detecting Alzheimer's disease and therapeutic methods for treating the same.

    摘要翻译： 提供分离的核酸分子编码人类PS1基因产物。 还提供了突变体PS1多肽，载体，宿主细胞以及用于制备它的重组方法也是如此。 本发明进一步涉及鉴定PS1多肽及其突变体的活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测阿尔茨海默氏病的诊断方法和用于治疗它们的治疗方法。

    REDUCTION OF BETA-AMYLOID LEVELS BY TREATMENT WITH THE SMALL MOLECULE DIFFERENTIATION-INDUCING FACTOR
    4.
    发明申请
    REDUCTION OF BETA-AMYLOID LEVELS BY TREATMENT WITH THE SMALL MOLECULE DIFFERENTIATION-INDUCING FACTOR 审中-公开
    通过用小分子差异诱导因子进行治疗降低β-淀粉样蛋白水平

    公开(公告)号：US20100311726A1

    公开(公告)日：2010-12-09

    申请号：US12669101

    申请日：2008-07-16

    申请人： Michael Myre ,  Wilma Wasco ,  Rudolph E. Tanzi

    发明人： Michael Myre ,  Wilma Wasco ,  Rudolph E. Tanzi

    IPC分类号： A61K31/12 ,  A61K31/445 ,  A61K31/27 ,  A61K31/55 ,  A61K31/4355 ,  A61K31/13 ,  A61K31/498 ,  A61P25/00 ,  A61P25/28

    CPC分类号： A61K31/055

    摘要： The present invention relates to novel uses for a family of small molecules, Differentiation-Inducing Factors (DIFs). It has been discovered that DIFs surprisingly can alter the metabolic processing of amyloid precursor protein (APP) and in turn reduce the level of secreted Aβ. The metabolic processing of other γ-secretase substrates normally present in cells (Notch and APLP1) is not affected when treated with DIF. The invention provides methods for reducing Aβ production in mammalian cells that express APP by administering DIF-I, DIF-2, DIF-3, a functionally equivalent analog and or any combination thereof. The invention also provides methods for treating and/or preventing Alzheimer's disease by preferentially reducing Aβ production.

    摘要翻译： 本发明涉及小分子家族，分化诱导因子（DIF）的新用途。 已经发现DIF令人惊讶地可以改变淀粉样蛋白前体蛋白（APP）的代谢过程，并且反过来降低分泌的A＆bgr的水平。 通常存在于细胞（Notch和APLP1）中的其他γ-分泌酶底物的代谢处理在用DIF处理时不受影响。 本发明提供降低A＆Bgr的方法; 通过施用DIF-1，DIF-2，DIF-3，功能等同的类似物或其任何组合来表达APP的哺乳动物细胞中的产生。 本发明还提供了通过优先降低Aβ作用治疗和/或预防阿尔茨海默氏病的方法。 生产。